Expression of β-catenin, MUC1 and c-Met in diffuse-type gastric carcinomas: Correlations with tumour progression and prognosis

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4635-4641

  Retterspitz, Monika F ^a   Mönig, Stefan P ^a   Schreckenberg, Stephanie ^a   Schneider, Paul M ^b   Hölscher, Arnulf H ^a   Dienes, Hans P ^a   Baldus, Stephan E ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Catenin; c Met; Gastric cancer; Immunohistology; MUC1; Prognosis

Indexed keywords

BETA CATENIN; MUCIN 1; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL; TUMOR GROWTH;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOMA, SIGNET RING CELL; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUCIN-1; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 78650237836     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
2. Behrens J: Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 18: 15-30, 1999.
3. Baldus SE, Mönig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, Schneider PM, Thiele J, Hölscher AH and Dienes HP: MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 10: 2790-2796, 2004.
4. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-25, 2003.
5. Rosario M and Birchmeier W: How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 13: 328-335, 2003
6. Siewert JR, Hölscher AH, Becker K and Gossner W: Cardia cancer: attempt at a therapeutically relevant classification. Chirurg 58: 25-32, 1987.
7. Ohno S, Tomisaki S, Oiwa H, Sakaguchi Y, Ichiyoshi Y, Maehara Y and Sugimachi K: Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg 180: 577-582, 1995.
8. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M and Farthing MJ: Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 112: 46-54, 1997.
9. Ramesh S, Nash J and McCulloch PG: Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer 81: 1392-1397, 1999
10. Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang DC and Yang JM: Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 8: 987-993, 2002.
11. Miyazawa K, Iwaya K, Kuroda M, Harada M, Serizawa H, Koyanagi Y, Sato Y, Mizokami Y, Matsuoka T and Mukai K: Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. Virchows Arch 437: 508-513, 2000.
12. Brabletz T, Jung A and Kirchner T: Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch 441: 1-11, 2002.
13. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A and Armas A: Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155: 527-536, 1999.
14. Aihara R, Mochiki E, Nakabayashi T, Akazawa K, Asao T and Kuwano H: Clinical significance of mucin phenotype, beta-catenin and matrix metalloproteinase 7 in early undifferentiated gastric carcinoma. Br J Surg 92: 454-462, 2005.
15. Grabsch H, Takeno S, Noguchi T, Hommel G, Gabbert HE and Mueller W: Different patterns of beta-catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome. Histopathology 39: 141-149, 2001.
16. Joo YE, Rew JS, Kim HS, Choi SH, Park CS and Kim SJ: Changes in the E-cadherin-catenin complex expression in early and advanced gastric cancers. Digestion 64: 111-119, 2001.
17. Nabais S, Machado JC, Lopes C, Seruca R, Carneiro F and Sobrinho-Simoes M: Patterns of beta-catenin expression in gastric carcinoma: clinicopathological relevance and mutation analysis. Int J Surg Pathol 11: 1-9, 2003.
18. Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL and Niehans GA: Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res 55: 2681-2690, 1995.
19. Sakamoto H, Yonezawa S, Utsunomiya T, Tanaka S, Kim YS and Sato E: Mucin antigen expression in gastric carcinomas of young and old adults. Hum Pathol 28: 1056-1065, 1997.
20. Baldus SE, Zirbes TK, Engel S, Hanisch FG, Mönig SP, Lorenzen J, Glossmann J, Fromm S, Thiele J, Pichlmaier H and Dienes HP: Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1 and MUC2 with the histopathological subtype and prognosis of gastric carcinomas. Int J Cancer 79: 133-138, 1998.
21. Reis CA, David L, Seixas M, Burchell J and Sobrinho-Simoes M: Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 79: 402-410, 1998.
22. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS and Sato E: Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 4: 2605-2614, 1998.
23. Akyurek N, Akyol G, Dursun A, Yamac D and Gunel N: Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. Pathol Res Pract 198: 665-674, 2002.
24. Wang JY, Chang CT, Hsieh JS, Lee LW, Huang TJ, Chai CY and Lin SR: Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas. J Surg Oncol 83: 253-260, 2003.
25. Wang RQ and Fang DC: Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol 56: 378-384, 2003.
26. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI and Kim WH: MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 92: 1427-1434, 2001.
27. Lee HS, Lee HK, Kim HS, Yang HK and Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200: 39-46, 2003.
28. Shinozaki E, Adachi S, Shoda J, Kawamoto T, Suzuki H, Irimura T and Ohkohchi N: Subcellular localization of MUC1 recognized by a monoclonal antibody MY.IE12 correlates with postsurgical prognosis in differentiated-type gastric carcinomas of stage II and III. Int J Oncol 25: 1257-1265, 2004.
29. Bara J, Imberty A, Perez S, Imai K, Yachi A and Oriol R: A fucose residue can mask the MUC-1 epitopes in normal and cancerous gastric mucosae. Int J Cancer 54: 607-613, 1993.
30. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y and Tahara E: Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 55: 72-75, 1993.
31. Kaji M, Yonemura Y, Harada S, Liu X, Terada I and Yamamoto H: Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 3: 393-404, 1996.
32. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura T, Miwa K, Endo Y, Yamamoto H and Watanabe H: The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82: 2112-2122, 1998.
33. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T and Nakano H: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999.
34. Huang TJ, Wang JY, Lin SR, Lian ST and Hsieh JS: Overexpression of the c-met protooncogene in human gastric carcinoma - correlation to clinical features. Acta Oncol 40: 638-643, 2001.
35. Wu CW, Li AF, Chi CW, Chung WW, Liu TY, Lui WY and P'Eng FK: Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5: 817-822, 1998.
36. Heideman DA, Snijders PJ, Bloemena E, Meijer CJ, Offerhaus GJ, Meuwissen SG, Gerritsen WR and Craanen ME: Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J Pathol 194: 428-435, 2001.
37. Kubicka S, Claas C, Staab S, Kuhnel F, Zender L, Trautwein C, Wagner S, Rudolph KL and Manns M: p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection and prognosis. Dig Dis Sci 47: 114-121, 2002.
38. Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P and Comoglio PM: Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6: 1997-2003, 1991.
39. Tang Z, Zhao M, Ji J, Yang G, Hu F, He J, Shen H, Gao Z, Zhao A, Li J and Lu Y: Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep 11: 333-339, 2004.
40. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H and Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232, 1992.
41. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I and Yamamoto H: Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55: 475-481, 1998.
42. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S and Polakis P: Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-1026, 1996.
43. Li Y, Bharti A, Chen D, Gong J and Kufe D: Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 18: 7216-7224, 1998.
44. Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D: MUCl oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 65: 10413-10422, 2005.